The record
Written from the 2 reports below. Nothing here is unsourced.
- US President Donald Trump announced steep tariffs on imported generic medicines, to take effect starting August 2028.
- Generic drugs will keep a zero per cent tariff for two years from August 1, 2026, then rise to 100 per cent for one year and 200 per cent thereafter, a move he says aims to bring pharmaceutical manufacturing to the US.
- India, the largest exporter of generic drugs to the US, could be affected — it exported USD 9.7 billion worth of pharmaceuticals to the US in 2025, 38 per cent of its total pharma exports.
- Indian generic medicines are widely used for conditions like hypertension, diabetes and cancer, so the announcement matters for both Indian exporters and US patients.
What to watch next
- Whether Indian pharma companies respond by setting up or expanding manufacturing in the US during the two-year zero-tariff window
- Details on how the tariffs will apply to India's specific categories of generic drug exports
- Any response from the Indian government or pharma industry bodies to the announced tariff schedule
What changed2
Every report on this story, newest first. Times are when each outlet published.
Coverage2
2 reports
English national2
All filed from India
Named United States · India · Donald Trump · Global Trade Research Initiative · Indian Drug Manufacturers Association · Mahesh Doshi · Namit Joshi · Pharmaceutical Exports Council of India · Systematix Group · Vishal Manchanda
The 2 reports are listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.